TVM Capital

Seasoned life sciences venture capitalist with over 25 years of experience, joining TVM in 2012 to drive overall investment strategy. Has directed numerous late-stage and early-stage companies across therapeutics and medtech. Previously managed life science investments at Toronto-based VG Partners where he founded the life science practice, and earlier held positions at Amgen conducting immunology and oncology research.

Managing Partner responsible for TVM Capital Life Science's overall investment strategy and global fund operations, joining TVM in 2000. He previously worked at Zeneca and McKinsey and holds a doctorate from LMU and an MBA from Harvard Business School.

Managing Partner who joined TVM in 2012 and drives investment strategy for the TVM LSI funds, with more than 25 years of venture capital experience. He previously founded the life science practice at VG Partners and worked at Caisse de Depot, MDS Capital and MedTech Partners.

General Partner focusing on evaluation of deal opportunities and investment management for therapeutics, working closely with strategic partner Eli Lilly. He is an experienced clinical development executive with prior senior roles at Axcan Pharma, Caprion, Bioniche and Quintiles.

Executive with extensive experience building and managing clinical programs across all drug development phases. Specializes in deal evaluation and therapeutic investment management, partnering closely with Eli Lilly's drug development division. Previously held senior clinical and medical leadership roles at Axcan Pharma, Caprion Pharmaceuticals, and Bioniche Life Sciences.

CFO and Managing Partner (Finance) since 2012, having joined TVM in 2000, overseeing finance operations, fund administration, investor relations and fundraising. He has over 23 years of venture capital experience and previously worked in corporate finance at KPMG Munich.

Joined TVM in 2020 with preclinical drug development expertise spanning hit identification through IND-enabling studies. Worked six years as a preclinical scientist at pharmaceutical startups Versantis and Mperia Therapeutics. Holds a Ph.D. in biopharmacy from the University of Paris-Saclay.

Principal and neurobiologist with broad pharmaceutical development, medical affairs and regulatory experience. He has served as CEO of project-focused companies and held clinical development roles at enGene, Actavis and Aptalis Pharma.

Neurobiologist with broad pharmaceutical industry expertise across the full lifecycle of drug development, medical affairs, and regulatory matters for small molecules, biologics, and gene therapy. Has served as CEO for multiple project-focused therapeutic companies in oncology, immunology, and neuroscience, and held clinical leadership positions at various pharma firms.

Principal who joined TVM in 2020 after working on the Global Healthcare Team at Societe Generale Corporate & Investment Banking on cross-border healthcare M&A. He holds a Master's in International Finance and Economics.

Principal who joined TVM in 2020 with hands-on experience in preclinical drug development, previously working as a Preclinical Development Scientist at pharmaceutical startups. She holds a PhD in Biopharmacy from the University of Paris-Saclay.

Senior Associate who joined TVM in 2026 with a background in biomedical sciences, technology and AI. She was previously a senior consultant at McKinsey & Company advising pharma, biotech, medtech and healthcare clients.